Recent

% | $
Quotes you view appear here for quick access.

Palatin Technologies Inc. Message Board

  • markitcorrect markitcorrect Sep 13, 2013 9:51 AM Flag

    Question for the Board

    Did PH II show that the efficacy of Brem tested, was effective in moving the dial for women suffering from FSD? Everything I've read (mostly Spana's propaganda) indicated that PH III would be a breeze. So why are we lingering in the

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think the 1.75 mg dose was probably effective. But the simplest and straightest answer to the following by Adam Fuerstein would have been to just show an analysis of the data of the 287 patients that finished the 3 months of treatment. But Palatin has been unwilling to do that.

      "We should have been provided data on the 397 patients enrolled and randomized, or the 287 patients who completed the study. What Palatin gives us, instead, is a post-hoc concoction of patients treated with bremalanotide or placebo for only one month.

      Why? Palatin doesn't say, but it's safe to assume the analysis of the study's pre-specified primary endpoint was negative. Palatin tries to pass off an irrelevant efficacy analysis as the real deal, but of course, we're all smarter than that. "

 
PTN
0.490.00(-0.91%)Feb 12 4:00 PMEST